Salarius announces two animal studies peer-reviewed publications

Salarius Pharmaceuticals (SLRX) announces that two animal studies recently published in peer-reviewed journals provide additional insight into the role of inhibiting lysine-demethylase 1, a well-validated target in hematologic and solid tumors. Salarius’ seclidemstat is a first-in-class, orally bioavailable LSD1 inhibitor that is being evaluated in an investigator-initiated Phase 1/2 clinical study at MD Anderson Cancer Center (MDACC) as a potential treatment for myelodysplastic syndrome, or MDS, and chronic myelomonocytic leukemia, or CMML, in patients with limited treatment options. Salarius also announces continued progress in its planned merger with Decoy Therapeutics. Under the definitive agreement announced on January 13, Decoy will merge with a wholly owned subsidiary of Salarius, subject to the closing conditions set forth in the agreement. The newly formed company will be named Decoy Therapeutics. The proposed transaction, if consummated, is expected to facilitate multiple value-creating inflection points with Decoy’s pipeline of peptide conjugate therapeutics engineered by its IMP3ACT platform, which allows for the rapid computational design and manufacturing of innovative peptide conjugate therapeutics. Decoy’s product pipeline targets unmet needs in respiratory infectious diseases and gastroenterology oncology indications.